Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
B-Raf V600E refers to a specific mutation in the BRAF gene, where the amino acid valine (V) at position 600 is replaced by glutamic acid (E). This single-point mutation results in a constitutively active form of the B-Raf protein, a serine/threonine kinase involved in cell signaling pathways that regulate cell growth and division. The mutant protein can signal independently of upstream Ras activation, leading to continuous MAPK pathway activity, driving uncontrolled cellular proliferation and survival. It is a therapeutic target in multiple cancer types and can be detected through DNA sequencing and immunohistochemistry.
Inhibition of mutated B-Raf kinase activity.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on B-Raf V600E (BRAF V600E).